蛋白S-棕榈酰化修饰及其在肿瘤中的作用

doi:10.3760/cma.j.cn371439-20240522-00130

摘要/Abstract

摘要：

蛋白S-棕榈酰化是一种可逆的脂质翻译后修饰，具有调控蛋白定位、稳定性、蛋白间相互作用等功能。棕榈酰转移酶通过催化反应将棕榈酸酯添加至蛋白半胱氨酸残基上，而棕榈酰酯的去除主要通过酰基蛋白硫酯酶的催化。一些肿瘤相关蛋白S-棕榈酰化修饰发生异常改变，并且与肿瘤细胞增殖、侵袭、转移、耐药及肿瘤免疫应答等生物学过程密切相关。进一步探讨蛋白S-棕榈酰化修饰的特点及其在肿瘤进展中的作用，以期为靶向蛋白S-棕榈酰化的肿瘤治疗策略提供新的思路。

关键词: 肿瘤, 蛋白质加工，转译后, S-棕榈酰化, 棕榈酰转移酶, 酰基蛋白硫酯酶

Abstract:

Protein S-palmitoylation is a reversible post-translational modification of lipids that regulates protein localization， stability and protein-protein interactions. The thioesterification of palmitate to internal cysteine residues is catalyzed by palmitoyltransferase， while the removal of palmitate is mainly catalyzed by acyl-protein thioesterase. The S-palmitoylation of some tumor-related proteins is abnormally altered in tumor， which is closely related to the biological processes such as tumor cell proliferation， invasion， metastasis， drug resistance and immune response. Furtherly， exploring the characteristics of protein S-palmitoy-lation and its role in tumor progression could deliver new ideas in targeting protein S-palmitoylation for tumor therapy.

Key words: Neoplasms, Protein processing， post-translational, S-palmitoylation, Palmitoyltransfe-rases, Acyl-protein thioesterases

谌亮, 李营歌, 郑斯豪, 张偲, 颜琦璐, 宋启斌, 姚颐. 蛋白S-棕榈酰化修饰及其在肿瘤中的作用[J]. 国际肿瘤学杂志, 2024, 51(12): 769-773.

Chen Liang, Li Yingge, Zheng Sihao, Zhang Cai, Yan Qilu, Song Qibin, Yao Yi. Protein S-palmitoylation and its role in tumor[J]. Journal of International Oncology, 2024, 51(12): 769-773.

参考文献 40

[1]	Hanahan D. Hallmarks of cancer: new dimensions[J]. Cancer Discov, 2022, 12(1): 31-46. DOI: 10.1158/2159-8290.CD-21-1059. pmid: 35022204
[2]	Geffen Y, Anand S, Akiyama Y, et al. Pan-cancer analysis of post-translational modifications reveals shared patterns of protein regulation[J]. Cell, 2023, 186(18): 3945-3967.e26. DOI: 10.1016/j.cell.2023.07.013. pmid: 37582358
[3]	Zaballa ME, van der Goot FG. The molecular era of protein S-acylation: spotlight on structure, mechanisms, and dynamics[J]. Crit Rev Biochem Mol Biol, 2018, 53(4): 420-451. DOI: 10.1080/10409238.2018.1488804.
[4]	Main A, Fuller W. Protein S-palmitoylation: advances and challenges in studying a therapeutically important lipid modification[J]. FEBS J, 2022, 289(4): 861-882. DOI: 10.1111/febs.15781.
[5]	Puthenveetil R, Gómez-Navarro N, Banerjee A. Access and utilization of long chain fatty acyl-CoA by zDHHC protein acyltransferases[J]. Curr Opin Struct Biol, 2022, 77: 102463. DOI: 10.1016/j.sbi.2022.102463.
[6]	Salaun C, Locatelli C, Zmuda F, et al. Accessory proteins of the zDHHC family of S-acylation enzymes[J]. J Cell Sci, 2020, 133(22): jcs251819. DOI: 10.1242/jcs.251819.
[7]	Zmuda F, Chamberlain LH. Regulatory effects of post-translational modifications on zDHHC S-acyltransferases[J]. J Biol Chem, 2020, 295(43): 14640-14652. DOI: 10.1074/jbc.REV120.014717.
[8]	Liao D, Huang Y, Liu D, et al. The role of S-palmitoylation in neurological diseases: implication for zDHHC family[J]. Front Pharmacol, 2024: 1342830. DOI: 10.3389/fphar.2023.1342830.
[9]	Jin J, Zhi X, Wang X, et al. Protein palmitoylation and its pathophysiological relevance[J]. J Cell Physiol, 2021, 236(5): 3220-3233. DOI: 10.1002/jcp.30122. pmid: 33094504
[10]	Won SJ, Cheung See Kit M, Martin BR. Protein depalmitoylases[J]. Crit Rev Biochem Mol Biol, 2018, 53(1): 83-98. DOI: 10.1080/10409238.2017.1409191.
[11]	Ko PJ, Dixon SJ. Protein palmitoylation and cancer[J]. EMBO Rep, 2018, 19(10): e46666. DOI: 10.15252/embr.201846666.
[12]	Tate EW, Soday L, de la Lastra AL, et al. Protein lipidation in cancer: mechanisms, dysregulation and emerging drug targets[J]. Nat Rev Cancer, 2024, 24(4): 240-260. DOI: 10.1038/s41568-024-00666-x. pmid: 38424304
[13]	Punekar SR, Velcheti V, Neel BG, et al. The current state of the art and future trends in RAS-targeted cancer therapies[J]. Nat Rev Clin Oncol, 2022, 19(10): 637-655. DOI: 10.1038/s41571-022-00671-9. pmid: 36028717
[14]	Zhou Y, Hancock JF. RAS nanoclusters are cell surface transducers that convert extracellular stimuli to intracellular signalling[J]. FEBS Lett, 2023, 597(6): 892-908. DOI: 10.1002/1873-3468.14569. pmid: 36595205
[15]	Remsberg JR, Suciu RM, Zambetti NA, et al. ABHD17 regulation of plasma membrane palmitoylation and N-Ras-dependent cancer growth[J]. Nat Chem Biol, 2021, 17(8): 856-864. DOI: 10.1038/s41589-021-00785-8. pmid: 33927411
[16]	Goloshvili G, Barbakadze T, Mikeladze D. Sodium nitroprusside induces H-Ras depalmitoylation and alters the cellular response to hypoxia in differentiated and undifferentiated PC12 cells[J]. Cell Biochem Funct, 2019, 37(7): 545-552. DOI: 10.1002/cbf.3431. pmid: 31429100
[17]	Busquets-Hernández C, Triola G. Palmitoylation as a key regulator of ras localization and function[J]. Front Mol Biosci, 2021, 8: 659861. DOI: 10.3389/fmolb.2021.659861.
[18]	Zhang M, Zhou L, Xu Y, et al. A STAT3 palmitoylation cycle promotes TH17 differentiation and colitis[J]. Nature, 2020, 586(7829): 434-439. DOI: 10.1038/s41586-020-2799-2.
[19]	Zhang Z, Li X, Yang F, et al. DHHC9-mediated GLUT1 S-palmitoylation promotes glioblastoma glycolysis and tumorigenesis[J]. Nat Commun, 2021, 12(1): 5872. DOI: 10.1038/s41467-021-26180-4.
[20]	Wang L, Cai J, Zhao X, et al. Palmitoylation prevents sustained inflammation by limiting NLRP3 inflammasome activation through chaperone-mediated autophagy[J]. Mol Cell, 2023, 83(2): 281-297.e10. DOI: 10.1016/j.molcel.2022.12.002. pmid: 36586411
[21]	Zhang G, Jiang P, Tang W, et al. CPT1A induction following epigenetic perturbation promotes MAVS palmitoylation and activation to potentiate antitumor immunity[J]. Mol Cell, 2023, 83(23): 4370-4385.e9. DOI: 10.1016/j.molcel.2023.10.043.
[22]	Yao H, Lan J, Li C, et al. Inhibiting PD-L1 palmitoylation enhances T-cell immune responses against tumours[J]. Nat Biomed Eng, 2019, 3(4): 306-317. DOI: 10.1038/s41551-019-0375-6. pmid: 30952982
[23]	Kharbanda A, Walter DM, Gudiel AA, et al. Blocking EGFR palmitoylation suppresses PI3K signaling and mutant KRAS lung tumorigenesis[J]. Sci Signal, 2020, 13(621): eaax2364. DOI: 10.1126/scisignal.aax2364.
[24]	Fan X, Fan J, Yang H, et al. Heterogeneity of subsets in glioblastoma mediated by Smad3 palmitoylation[J]. Oncogenesis, 2021, 10(10): 72. DOI: 10.1038/s41389-021-00361-8.
[25]	Yuan M, Chen X, Sun Y, et al. ZDHHC12-mediated claudin-3 S-palmitoylation determines ovarian cancer progression[J]. Acta Pharm Sin B, 2020, 10(8): 1426-1439. DOI: 10.1016/j.apsb.2020.03.008.
[26]	Pei X, Li KY, Shen Y, et al. Palmitoylation of MDH2 by ZDHHC18 activates mitochondrial respiration and accelerates ovarian cancer growth[J]. Sci China Life Sci, 2022, 65(10): 2017-2030. DOI: 10.1007/s11427-021-2048-2. pmid: 35366151
[27]	Chen L, Xing X, Zhu Y, et al. Palmitoylation alters LDHA activity and pancreatic cancer response to chemotherapy[J]. Cancer Lett, 2024, 587: 216696. DOI: 10.1016/j.canlet.2024.216696.
[28]	Chen QT, Zhang ZY, Huang QL, et al. HK1 from hepatic stellate cell-derived extracellular vesicles promotes progression of hepatocellular carcinoma[J]. Nat Metab, 2022, 4(10): 1306-1321. DOI: 10.1038/s42255-022-00642-5.
[29]	Lin Z, Agarwal S, Tan S, et al. Palmitoyl acyltransferase ZDHHC7 inhibits androgen receptor and suppresses prostate cancer[J]. Oncogene, 2023, 42(26): 2126-2138. DOI: 10.1038/s41388-023-02718-2. pmid: 37198397
[30]	Bu J, Zhong W, Li M, et al. CD82 palmitoylation site mutations at Cys5+Cys74 affect EGFR internalization and metabolism through recycling pathway[J]. Acta Biochim Biophys Sin (Shanghai), 2022, 54(3): 400-408. DOI: 10.3724/abbs.2022011.
[31]	Sadeghi RS, Kulej K, Kathayat RS, et al. Wnt5a signaling induced phosphorylation increases APT1 activity and promotes melanoma metastatic behavior[J]. Elife, 2018, 7: e34362. DOI: 10.7554/eLife.34362.
[32]	McClellan B, Wilson CN, Brenner AJ, et al. Flotillin-1 palmitoyla-tion is essential for its stability and subsequent tumor promoting capabilities[J]. Oncogene, 2024, 43(14): 1063-1074. DOI: 10.1038/s41388-024-02946-0. pmid: 38374406
[33]	Tomić G, Sheridan C, Refermat AY, et al. Palmitoyl transferase ZDHHC20 promotes pancreatic cancer metastasis[J]. Cell Rep, 2024, 43(5): 114224. DOI: 10.1016/j.celrep.2024.114224.
[34]	Sun Y, Zhang H, Meng J, et al. S-palmitoylation of PCSK9 induces sorafenib resistance in liver cancer by activating the PI3K/AKT pathway[J]. Cell Rep, 2022, 40(7): 111194. DOI: 10.1016/j.celrep.2022.111194.
[35]	Kadry YA, Lee JY, Witze ES. Regulation of EGFR signalling by palmitoylation and its role in tumorigenesis[J]. Open Biol, 2021, 11(10): 210033. DOI: 10.1098/rsob.210033.
[36]	Sun Y, Zhu L, Liu P, et al. ZDHHC2-mediated AGK palmitoylation activates AKT-mTOR signaling to reduce sunitinib sensitivity in renal cell carcinoma[J]. Cancer Res, 2023, 83(12): 2034-2051. DOI: 10.1158/0008-5472.CAN-22-3105.
[37]	Zhao C, Yu H, Fan X, et al. GSK3 β palmitoylation mediated by ZDHHC4 promotes tumorigenicity of glioblastoma stem cells in temozolomide-resistant glioblastoma through the EZH2-STAT3 axis[J]. Oncogenesis, 2022, 11(1): 28. DOI: 10.1038/s41389-022-00402-w.
[38]	Yang Y, Hsu JM, Sun L, et al. Palmitoylation stabilizes PD-L1 to promote breast tumor growth[J]. Cell Res, 2019, 29(1): 83-86. DOI: 10.1038/s41422-018-0124-5. pmid: 30514902
[39]	Du W, Hua F, Li X, et al. Loss of optineurin drives cancer immune evasion via palmitoylation-dependent IFNGR1 lysosomal sorting and degradation[J]. Cancer Discov, 2021, 11(7): 1826-1843. DOI: 10.1158/2159-8290.CD-20-1571. pmid: 33627378
[40]	Fan Y, Gao Y, Nie L, et al. Targeting LYPLAL1-mediated cGAS depalmitoylation enhances the response to anti-tumor immunotherapy[J]. Mol Cell, 2023, 83(19): 3520-3532.e7. DOI: 10.1016/j.molcel.2023.09.007. pmid: 37802025